Background: Preoperative oral capecitabine plus radiotherapy has been progressively adopted in oncology units to provide more convenient care to patients with rectal cancer, but little is known about adherence to this therapy.
Introduction
Combination radiochemotherapy for stage II and III rectal cancer is a therapeutic standard [1] , with oral capecitabine normally administered as an adjunct to radiotherapy, but this option also raises the question of therapeutic adherence.
Adherence is the degree to which patient behaviour corresponds to the therapeutic recommendations agreed on with the treating physician [2] . One very relevant aspect of research on therapeutic adherence is its measurement, as there is no validated instrument that helps to standardise its quantification [2] . In fact, the results of different evaluations on adherence depend in part on how it is assessed [3] , with a considerable variety of methods to choose from [4] .
One little-studied area in adherence research is preoperative treatment for rectal cancer with capecitabine. The fact that this is a short-term, oral treatment given prior to surgery suggests that adherence should be high [5] . The aim of this study is to evaluate adherence in this clinical situation in a prospective, multihospital cohort, using different methods to measure adherence.
Patients and methods
This was a prospective study and included patients diagnosed with incident, stage II and III rectal cancer, with an indication for treatment with capecitabine and radiotherapy as a neoadjuvant treatment to surgical intervention. Six hospitals in the Barcelona area participated between June 2012 and March 2014. Patients signed informed consent upon enrolment, and the study was approved by the Ethics Clinical Research Committee at the Bellvitge Hospital. Participants were followed up throughout the neoadjuvant treatment (5-6 weeks) or until definitive suspension of treatment due to disease progression, toxicity or patient decision. We excluded patients participating in clinical trials. Assuming an 80% adherence rate to the treatment in our population, we calculated needing a sample size of 102 to estimate adherence with 95% confidence and a precision of 6 5%. We anticipated a replacement rate of 10%.
Variables and source of data were obtained using the following: The review of the clinical record was the source for information on tumour characteristics, stage and treatment. The questionnaire on patientreported symptoms and adverse effects consisted of a specific list, revised by the investigating clinicians. Participants also responded to questions about comorbidities and the number of medicines they were taking in addition to the chemotherapy.
The Simplified Medication Adherence Questionnaire (SMAQ) [6] elicited information about participants' habits for taking medication, propensity to skip doses, timetables, adverse effects, omissions at the weekend and quantification over the previous week. Specially trained medical professionals administered the questionnaire. We categorised patients as non-adherent if their response to one or more questions on adherence was negative. The average pill count on dispensed and returned medication was carried out in the hospital pharmacy during planned appointments for prescription refills. Adherence was calculated from the number of pills prescribed, the pills returned and the days of treatment. Patients were categorised as adherent if they took 80%-110% [7] .
We evaluated participants' emotional state (depression and anxiety) using HADS, which is self-administered and has been validated in our country [8] . We also used the EORTC QLQ-C30, a validated tool for assessing quality of life in cancer patients over the previous week; it consists of 30 questions or items related to physical, emotional, social and functional aspects [9] .
To analyse the determinants of non-adherence to oral treatment, we calculated the odds ratio (OR) and its 95% confidence interval (CI) using non-conditional logistic regression models. In order to predict adherence, we have restricted the statistical analysis to pre-treatment variables. Each variable whose univariate test has shown a P value of less than 0.25 were adjusted for clinical variables (age, sex and stage) [10] . The degree of concordance between the three methods used to measure adherence was estimated using the modified Kappa statistic [11] . We used the SPSS statistical package (version 21.0).
Results
One hundred nineteen participants were included in the study. Supplementary Figure S1 (available at Annals of Oncology online) presents the flow chart for participants during the course of the study. Table 1 shows the characteristics of the patients. There were 76.3% of these with comorbidity; hypertension was the most frequent condition. All patients received concomitant radiotherapy, and 116 finally underwent surgery; the other 2 patients could not due to disease progression. With regard to capecitabine treatment, this was temporarily interrupted in seven patients (5.9%) and definitively in five (4.2%) due to toxicity.
Overall, physicians' reports did not include any mention of non-adherence, whereas adherence was 83.2% according to the SMAQ questionnaire and 67.9% according to the pill count in the hospital pharmacy. Thus, the degree of concordance was very high between the clinical history and the SMAQ but more moderate with the pill count ( Table 2) .
The univariable and multivariable analyses with the different independent variables in relation to adherence (measured by pill count) are presented in Table 3 , along with the percentage of adherents according to the categories of each variable. In the multivariable analysis, we did not observe an association between adherence and any of the demographic or disease-related variables. With regard to the HADS, we observed that participants with low levels of anxiety at treatment initiation were seven times as adherent as participants with high levels (OR 6.96, 95% CI 1.48-32.70). There was also a significant, although lower magnitude, association for depression and anxiety together; participants with a higher global score at treatment initiation were less adherent ( Table 3 ). The EORTC QLQ-30 pre-treatment did not bring to light any significant association for global quality of life. 
Discussion
The main finding of this study is the different result for adherence to preoperative chemotherapy with capecitabine in the context of radiochemotherapy for rectal cancer, according to the method of assessment. Adherence varied from 100% (clinical history) to 83.2% (self-report) to 67.9% (pill count). We know that selfreport tends to overestimate adherence compared to indirect methods that do not depend on patient opinion [12] , in part due to social desirability bias [13] , wherein patients respond in the way they believe will please the health professional evaluating them. Patients and professionals may also have different perceptions regarding what adherence means. The data on adherence observed in this study are consistent with the range of values observed in previous studies [4] . In a sample of 24 participants with rectal cancer, Figueiredo [14] measured adherence by means of pill count, finding that 94.3% were adherent. In a single-site intervention study, evaluating the impact of pharmaceutical care, also in 24 participants with colorectal cancer, Simmons et al. [15] observed an adherence rate of 87.2% in the control group and 96.8% in the intervention group, using electronic monitoring as the method of assessment. Bhattachayn et al. [16] measured adherence with self-report in colorectal and breast cancer patients, reporting a 72.7% rate of adherence, while an intervention study in Germany [17] observed a rate of 79.5% in the pre-intervention phase, using electronic monitoring. Globally, these data are similar to those we obtained when using self-report, and better than those obtained through pill counts. Our results show the need for health professionals to systematically evaluate therapeutic adherence as a routine part of the treatment process, once the reliability of the assessment method has been checked [18] . Our failure to identify any predictive factors that would allow us to define a subgroup of patients at high risk for non-adherence, underlines the importance of systematic evaluation in all patients. Indeed, the association between sociodemographic or disease-related variables and poor adherence shows mixed results in recent literature reviews [4] . However, we did find a clear association for anxiety at treatment initiation, suggesting that this is a clinically manageable risk factor to take into account when detected.
Some studies have shown how to improve adherence through pharmaceutical care and education strategies [17] , and they also explore patient concerns about their disease, the need to have better information about it, the potential adverse effects of treatment and how to manage them [16] . These strategies, combined with discussions with patients about the medical aspects related to treatment and the disease prognosis, may be useful in reducing non-adherence to capecitabine.
Some limitations of this study should be considered when interpreting results. Physician-reported adherence was measured by means of a review of the data recorded in the clinical history. However, this could lead to an underestimation of their capacity to detect a problem. In addition, our exclusion of patients involved in clinical trials could have eliminated a group of patients with different characteristics and hypothetically greater adherence. On the other hand, one noteworthy feature of this study, which attests to its representativeness to usual clinical practice, is its multicentre design and its complete lack of attrition.
All in all, we observed notable differences in adherence according to the measurement technique in rectal cancer patients who were candidates for treatment with radical intent with preoperative radiochemotherapy. Health professionals should assess adherence problems with the patient during the consultation, especially the presence of anxiety at treatment initiation, in order to identify patients at risk of non-adherence. Pharmacists could also monitor the pill count at the end of the treatment and inform the physician about any adherence problems observed. 
